Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

lowering agent for high risk patients for whom conventional therapies are not sufficient. This potential blockbuster is a very Genzyme-like product. It provides significant benefit over the standard of care, targets a well-defined and severely ill patient population, and offers meaningful revenue and earnings potential."

"We feel that Genzyme is the perfect partner for Isis and for mipomersen," said Stanley Crooke, chairman, president and chief executive officer of Isis. "We have been very pleased with the quality and depth of interest in this flagship drug in our cardiovascular pipeline, and as we evaluated the licensing terms from various parties, we felt that Genzyme would value mipomersen appropriately as a pipeline-transforming product. This commitment to mipomersen, along with Genzyme's strength in drug development and marketing, made this relationship strategically compelling."

Mipomersen License

Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets. These trials have shown that the treatment is well-tolerated, has a strong safety profile, and works equally well in the presence and absence of other lipid-lowering therapies including statins. A weekly injectable therapeutic, mipomersen is being developed primarily for patients at significant cardiovascular risk who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins. The drug has strong, broad patent protection.

Mipomersen's initial indication will be for patients with familial hypercholesterolemia (FH), with an anticipated filing in 2009. There are approximately 1.5 million people in the United States and Europe with FH, an inherited
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... GLOBAL MARKETS , the global market for digital polymerase ... 2013. This is estimated to grow to $490 billion ... (CAGR) of 28.6%. , New digital PCR technology has ... the broader PCR field. The opportunities presented by this ...
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... SectorWatch.biz announces the,availability of MarketStats on public ... today., Investors can view all of SectorWatch.biz ... -- Click on MarketStats, Today,s MarketStats on ... (OTC Bulletin Board: CVBT), Boston,Scientific Corp. (NYSE: ...
... Innovations Inc.,(TSX: ATB) will hold its quarterly conference ... February 29, 2008. The call will follow the ... year results issued earlier that,day. Participants may access ... or 800-731-5774 or via the Company,s website at, ...
... 14 Accelerated Community Oncology,Research Network, Inc. ... Phase,2b clinical trial evaluating the efficacy of ... drug gemcitabine (Gemzar(R)) in patients,with metastatic breast ... after,treatment with bevacizumab (Avastin(R))., (Logo: ...
Cached Biology Technology:SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29 2Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx 2Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx 3
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
(Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
(Date:7/10/2014)... July 8, 2014 Fingerprint ... new design win (DW). An Asian OEM has selected FPC1021 ... production start in August 2014.   FPC is ... which has a planned date for start of mass production ... order of SEK 5M, for delivery in the first half ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... WI, JUNE 14, 2011 - Tropical maize proves to ... in USA Corn Belt maize. Most tropical maize varieties ... in U.S. growing regions by flowering late. This delayed ... useful genes and hindering their incorporation into maize hybrids ...
... our brain, and new research by University of California, ... that fear and other highly emotional experiences lead to ... (Tuesday, June 14) in advance of publication in the ... and colleagues report a new way for emotions to ...
... zone is predicted to be larger than average this ... this spring, according to an annual forecast by a ... Consortium, Louisiana State University and the University of Michigan. ... compiled annually by the U.S. Geological Survey (USGS). ...
Cached Biology News:Unique gene combinations control tropical maize response to day lengths 2Fear boosts activation of young, immature brain cells 2Fear boosts activation of young, immature brain cells 3Major flooding on the Mississippi River likely to cause large Gulf of Mexico dead zone 2Major flooding on the Mississippi River likely to cause large Gulf of Mexico dead zone 3
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... rolled steel with stove enamel coated (RAL 7035 ... Front, back and side windows ... lamps Internal adjustable tempered glass shelf ... Lighting 600 lux ...
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Biology Products: